Free Trial

HEALTHCARE: Thermo Fisher (TMO: A3 pos/ A-/A-): Q4 & FY24

HEALTHCARE

4th Quarter showing some improved momentum

  • Q4 revenue $11.4bn +4.7% yoy; ahead of 11.29bn consensus
  • Full year Revenue $42.88bn flat yoy
  • Will provide 2025 guidance in conference call at 08:30 EST
  • Operating Income $2,016 showed a margin improvement of 70bps to 17.7%
  • The company has previously guided for $75bn of capital deployment, of which 60-75% will be M&A, over next 5yrs.
56 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

4th Quarter showing some improved momentum

  • Q4 revenue $11.4bn +4.7% yoy; ahead of 11.29bn consensus
  • Full year Revenue $42.88bn flat yoy
  • Will provide 2025 guidance in conference call at 08:30 EST
  • Operating Income $2,016 showed a margin improvement of 70bps to 17.7%
  • The company has previously guided for $75bn of capital deployment, of which 60-75% will be M&A, over next 5yrs.